These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 2582304)
1. Chloroacryloyl amides and alpha-methylenelactones from naltrexone, oxymorphone and fentanyl. Archer S; Michael J; Michael M; Simon EJ; Abdelhamid EM; Nelson WL; Koolpe GA Neuropeptides; 1985 Feb; 5(4-6):395-8. PubMed ID: 2582304 [TBL] [Abstract][Full Text] [Related]
2. Opioid agonists and antagonists. 6-Desoxy-6-substituted lactone, epoxide, and glycidate ester derivatives of naltrexone and oxymorphone. Koolpe GA; Nelson WL; Gioannini TL; Angel L; Appelmans N; Simon EJ J Med Chem; 1985 Jul; 28(7):949-57. PubMed ID: 2409280 [TBL] [Abstract][Full Text] [Related]
3. Diastereomeric 6-desoxy-6-spiro-alpha-methylene-gamma-butyrolactone derivatives of naltrexone and oxymorphone. Selective irreversible inhibition of naltrexone binding in an opioid receptor preparation by a conformationally restricted michael acceptor ligand. Koolpe GA; Nelson WL; Gioannini TL; Angel L; Simon EJ J Med Chem; 1984 Dec; 27(12):1718-23. PubMed ID: 6209395 [TBL] [Abstract][Full Text] [Related]
9. Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones. Pasternak GW; Hahn EF J Med Chem; 1980 Jun; 23(6):674-6. PubMed ID: 6156240 [TBL] [Abstract][Full Text] [Related]
10. 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands. Fang X; Larson DL; Portoghese PS J Med Chem; 1997 Sep; 40(19):3064-70. PubMed ID: 9301669 [TBL] [Abstract][Full Text] [Related]
11. Orientation of the oxygen atom at C-6 as a determinant of agonistic activity in the oxymorphone series. Ronai AZ; Foldes FF; Hahn EF; Fishman J J Pharmacol Exp Ther; 1977 Mar; 200(3):496-500. PubMed ID: 66306 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and binding of 3H-oxymorphazone to rat brain membranes. Varga E; Toth G; Benyhe S; Hosztafi S; Borsodi A Life Sci; 1987 Apr; 40(16):1579-88. PubMed ID: 2436019 [TBL] [Abstract][Full Text] [Related]
14. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Michel ME; Bolger G; Weissman BA Methods Find Exp Clin Pharmacol; 1985 Apr; 7(4):175-7. PubMed ID: 2991678 [TBL] [Abstract][Full Text] [Related]
15. Preparation of [3H]-oxymorphazone and its binding to rat brain membranes. Borsodi A; Varga E; Toth G; Hosztafi S NIDA Res Monogr; 1986; 75():220-3. PubMed ID: 2448626 [TBL] [Abstract][Full Text] [Related]
16. Morphine analgesia after intrathecal administration of a narcotic agonist, chloroxymorphamine and antagonist, chlornaltrexamine. Larson AA; Armstrong MJ Eur J Pharmacol; 1980 Nov; 68(1):25-31. PubMed ID: 6161013 [No Abstract] [Full Text] [Related]
17. Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptors. Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW Neuropharmacology; 1990 Sep; 29(9):805-10. PubMed ID: 1963479 [TBL] [Abstract][Full Text] [Related]
18. Opioid agonist and antagonist activities of peripherally selective derivatives of naltrexamine and oxymorphamine. Botros S; Lipkowski AW; Larson DL; Stark PA; Takemori AE; Portoghese PS J Med Chem; 1989 Sep; 32(9):2068-71. PubMed ID: 2475628 [TBL] [Abstract][Full Text] [Related]
19. Irreversible opiate agonists and antagonists. III. Phenylhydrazone derivatives of naloxone and oxymorphone. Hahn EF; Itzhak Y; Nishimura S; Johnson N; Pasternak GW J Pharmacol Exp Ther; 1985 Dec; 235(3):846-50. PubMed ID: 2416910 [TBL] [Abstract][Full Text] [Related]
20. The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone. Takemori AE; Larson DL; Portoghese PS Eur J Pharmacol; 1981 Apr; 70(4):445-51. PubMed ID: 6263637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]